Upacicalcet Is a Novel Secondary Hyperparathyroidism Drug that Targets the Amino Acid Binding Site of Calcium-Sensing Receptor

Hirofumi Sato, Sei Murakami, Yusuke Horii, Go Nishimura, Ryosuke Iwai, Moritaka Goto, and Naoki Takahashi

Pharmaceuticals Research Laboratories, Sanwa Kagaku Kenkyusho Co., Ltd., Mie, Japan

Received February 18, 2022; accepted July 14, 2022

ABSTRACT

The human calcium-sensing receptor (CaSR) is a G protein-coupled receptor that maintains extracellular Ca\(^{2+}\) homeostasis by regulating the secretion of parathyroid hormone. Upacicalcet is a novel positive allosteric modulator of CaSR that is used for the treatment of secondary hyperparathyroidism. In the present study, to clarify the binding site of upacicalcet to CaSR, we conducted binding studies and agonistic activity studies in HEK-293T cells expressing human CaSR (intact and mutant) and an in silico docking-simulation analysis. As a result, upacicalcet competed with L-tryptophan and was thought to affect the amino acid binding site. In addition, the effects of substitutions at the amino acid binding site on the binding abilities to upacicalcet as well as the effects on receptor function as measured using inositol-1 monophosphate accumulation were examined. Upacicalcet interacted with several CaSR residues that constitute the amino acid binding site. Based on these results, we performed an in silico analysis and obtained a binding mode, consistent with the in vitro study results. Our study revealed that upacicalcet is a novel secondary hyperparathyroidism drug that targets the amino acid binding site of CaSR. Upacicalcet is expected to become a new treatment option for secondary hyperparathyroidism because the binding site differs from that of conventional drugs; consequently, it may be effective for patients who are not sensitive to conventional drugs, and it may have a superior safety profile.

SIGNIFICANCE STATEMENT

Upacicalcet interacts with several residues that constitute the amino acid binding site of the calcium-sensing receptor (CaSR) and shows a potent positive allosteric activity. This mechanism differs from those of conventional drugs. Therefore, upacicalcet can be regarded as a novel secondary hyperparathyroidism drug that acts on the amino acid binding site of CaSR.

Introduction

Secondary hyperparathyroidism (SHPT) is a major complication in hemodialysis patients, occurring as chronic kidney disease progresses. Decreased kidney function results in an inability to activate vitamin D, resulting in inadequate calcium absorption and low calcium levels in the blood. Parathyroid hormone (PTH) secreted by the parathyroid gland plays a role in maintaining calcium and phosphorus homeostasis, but the excessive secretion of PTH in an attempt to normalize a hypercalcemic condition suppresses the synthesis/secretion of calcium, and this is associated with increased risks of fractures, ectopic calcification, and cardiac dysfunction (Go et al., 2004; Cunningham et al., 2011).

PTH secretion from the parathyroid gland is regulated by the human calcium-sensing receptor (CaSR), one of the class C G protein-coupled receptors (GPCR) present on the surface of parathyroid cells. The same receptor group includes metabotropic glutamate receptors, GABA\(_{A}\) receptors, taste receptors, and orphan receptors (D’Souza-Li, 2006). In the extracellular N-terminal domain of CaSR, there is a Ca\(^{2+}\) binding pocket that senses the extracellular calcium level and a domain involved in homodimer assembly (Venus flytrap domain), and the activation of CaSR in the high calcium state suppresses the synthesis/secretion of PTH. On the other hand, under hypocalcemic conditions, the activity of CaSR is reduced, and PTH synthesis/secretion is promoted. This mechanism by which CaSR regulates PTH secretion is a key therapeutic target in SHPT (Lau et al., 2018).

Cinacalcet, evocalcet, and etelcalcetide are the major calcimimetics clinically used in SHPT treatment. All three drugs lower blood calcium levels by activating CaSR and inhibiting PTH secretion. Cinacalcet and evocalcet have been shown to interact with amino acid Glu837 in the seven-transmembrane region of CaSR, while etelcalcetide has been shown to interact with amino acid Glu837 in the seven-transmembrane region of CaSR.
with amino acid Cys482 in the extracellular region (Alexander et al., 2015; Miyazaki et al., 2018). Besides synthetic compounds, aromatic amino acids such as L-phenylalanine and L-tryptophan were also known to activate CaSR by binding to amino acid binding sites in the extracellular region (Geng et al., 2016).

Upacicalcet is a novel SHPT drug that was identified in "kokumi-flavor" studies of γ-glutamyl peptides, such as glutathione, and was approved in Japan for the treatment of SHPT in 2021 (Ueda et al., 1997; Broadhead et al., 2011; Amino et al., 2016; Hoy, 2021). Upacicalcet does not activate CaSR in the extracellular low calcium range and has a potent positive allosteric effect that enhances CaSR activity in an extracellular calcium concentration-dependent manner, similar to amino acids and cinacalcet (Broadhead et al., 2011; Miyazaki et al., 2018). On the other hand, it is not clear which part of CaSR interacts with upacicalcet, resulting in positive allosteric activity.

In this article, we conducted a study to clarify the binding sites of upacicalcet. First, we evaluated the activity of upacicalcet on CaSR as a measure of intracellular Ca^{2+} mobilization. Since upacicalcet has a positive allosteric effect similar to that of amino acids and cinacalcet, it was predicted to share a common binding site with either of these compounds. Since the chemical structure of upacicalcet is similar to that of amino acids, upacicalcet was expected to bind to the amino acid binding site of CaSR. To verify this hypothesis, we first conducted a competition study between upacicalcet and these compounds. Second, we predicted the amino acid residues of CaSR that were the most likely to interact with upacicalcet based on the previously reported crystal structure of the extracellular domain (ECD) region of CaSR (Geng et al., 2016; Zhang et al., 2016). We then performed binding studies and in vitro inositol-1-monophosphate (IP-1) accumulation assays for each predicted binding site using alanine-substituted mutant CaSR proteins. Finally, we performed an in silico docking-simulation analysis to evaluate the molecular dynamics stability and the detailed binding mode between upacicalcet and human CaSR.

Materials and Methods

Materials. Upacicalcet was obtained from EA Pharma. Cinacalcet hydrochloride was obtained from Amatek Chemical. L-tryptophan was purchased from FUJIFILM Wako Pure Chemical. The synthesis of plasmid vectors encoding full-length human CaSR (both wild-type (WT) and alanine-substituted) using pBapo-CMV Pur DNA (TaKaRa Bio) as a blank vector was entrusted to TaKaRa Bio. The substitution at Cys482 resulted in replacement with tyrosine (Alexander et al., 2015). The obtained plasmids were stored at −20°C until use. Tritium-labeled upacicalcet ([^3]H-upacicalcet) with a specific radioactivity of 93.1 GBq/mmol was synthesized at Sekisui Medical and stored at −80°C.

Cell Culture. HEK-293T (HEK) cells were purchased from RIKEN BRC. HEK cells stably expressing human CaSR were purchased from Multispan. These cells were cultured in Dulbecco’s Modified Eagle medium (DMEM; CORNING) supplemented with 10% inactivated FBS (CORNING) and puromycin (1 μg/mL; InvivoGen). When the cells reached 80% to 90% confluence, they were separated using trypsin and passed; the cells were cultured at 37°C and 5% CO2, and the number of passages was within 30x.

Intracellular Ca^{2+} Flux Measurement (Calcium Mobilization Assay). Intracellular Ca^{2+} mobilization was measured using the Fluo-4 NW Calcium Assay Kit (Molecular Probes). CaSR-HEK cells cultured to 80% to 100% confluence, the medium was removed, and 100 μL of Ca^{2+} assay buffer (1 × Hanks’ balanced salt solution, 20 mM HEPES, 2.5 mM probenecid, 1 mM MgSO4, 0.1 mM CaCl2, 0.1% bovine serum albumin) containing Fluo-4 mix dye was added. These plates were incubated at 37°C, 5% CO2 for 30 min and then incubated at room temperature for 15 min. Next, 50 μL of Ca^{2+} assay buffer containing upacicalcet (final concentration of 0, 10, or 1000 nM) was added, and the fluorescence intensity (excitation: 485 nm, emission: 525 nm) was measured using a fluorescence plate reader (SPECTRAMAX Gemini EM; Molecular Devices) for 20 s. Then, 50 μL of Ca^{2+} assay buffer containing various concentrations of upacicalcet and Ca^{2+} (final concentrations, 0.1–1.5 mM) was added, and the fluorescence intensity was measured for 60 s. The relative fluorescence unit (RFU) fold change was calculated using the following formula, and the concentration-response curve was generated using GraphPad Prism (GraphPad Software, ver. 6.05). Each test was performed three times with triplicate measurements per concentration point.

\[
RFU \text{ fold change} = \frac{MAX \text{ Signal level}^{-1}}{MIN \text{ Signal level}^{-2}}
\]

*1: Maximum value of fluorescence intensity within 60 s.
*2: Minimum value of fluorescence intensity within 20 s.

Isolation of CaSR-Expressed Membrane Proteins from Transfected HEK-293T Cells. HEK cells were cultured to 80% to 90% confluence in DMEM containing 10% FBS, Opti-MEM (Invitrogen) containing 16 μg/mL of the plasmid vector encoding either the WT or mutant full-length CaSR, and 48 μL/mL of Lipofectamine 2000 (ThermoFisher). The cells were cultured at 37°C and 5% CO2 for 24 h for transfection (Trans-HEK cells). The cells were isolated by trypsin and passed for 24 h under the same conditions and then transferred to DMEM medium containing 1 μg/mL of puromycin and passed repeatedly until the doubling time was reached at about 20 h. Cells were cultured to 80% to 100% confluence, washed with ice-cold Dulbecco’s phosphate-buffered saline (DPBS; Invitrogen), separated with trypsin, added to DMEM medium, and collected. The cell clumps were obtained at 500 × g for 10 min. To the cell clumps, homogenization buffer (50 mM Tris-HCl, 1 mM MgCl2, 10 mM KCl, pH 7.4) was added, and the cells were homogenized three times at 13,000 rpm for 30 s using a pellet homogenizer (KINECTICA) under ice-cold conditions. The resulting cell suspension was ultracentrifuged at 48,000 × g for 20 min at 4°C. The homogenization and ultracentrifugation were repeated three times, and the protein concentration of the obtained membrane protein fraction solution was assayed using the BCA protein assay kit (Pierce), diluted to 2 mg/mL, and stored at −80°C until use. The cell membranes of HEK cells and CaSR-HEK cells were prepared using the same procedure.

Confirmation of CaSR Expression Using Western Blot Analysis. HEK cells, HEK-CaSR cells, and Trans-HEK cells with a doubling time of about 20 h were collected, washed in DPBS, and radioimmunoprecipitation assay buffer A (BioDynamics Laboratory) containing protease inhibitors was added to lyse the cells. The lysis solution was centrifuged at 15,000 rpm at 4°C for 20 min, and the protein concentration in the supernatant was measured using the BCA protein assay kit. Laemmli buffer (Bio-Rad) containing 2-mercaptoethanol (one-tenth of the amount of Laemmli buffer) and Tris-HCl (moderate amount; for protein concentration adjustment) was added to make the protein concentration 2 mg/mL, and the solution was and heated at 95°C for 5 min, 4–20% Mini PROTEAN TGX gel (Bio-Rad) was set in the electrophoresis device (Mini PROTEAN Tetra cell, Bio-Rad) filled with 1× Tris/glycine/SDS buffer, and after sample application, the device was run at 200 V. The gels were transferred to polyvinylidene fluoride membranes using Trans-Blot Turbo Mini PVDF Transfer Packs (Bio-Rad) at 25 V for 30 min. The transferred membrane was blocked with polyvinylidene fluoride.
Anti-CaSR antibody [5C10, ADD] (ab19347; abcam) was used as the primary antibody for CaSR detection. Primary antibody was diluted 2000-fold with Can Get Signal solution 1 (TOYOBO). Anti-mouse IgG H&L HRP (ab205719; Bio-Rad) was used as the secondary antibody. Secondary antibody was diluted 5000-fold with Can Get Signal solution 2 (TOYOBO). Transfer membranes treated with the primary and secondary antibodies were colorized using the ECL prime Western Blotting Detection System (Amersham) and photographed using ChemiDoc XRS Plus (Bio-Rad).

Competitive Binding Study of Tryptophan and Cinacalcet Using a Scintillation Proximity Assay. WGA PEI Type A PVT SPA Scintillation Beads (PerkinElmer) were suspended in binding assay buffer (50 mM Tris-HCl, 1 mM MgCl2, 0.5% 3-[3-cholamidopropyl]dimethylammonio)-1-propanesulfonic acid, pH 7.4), and HEK or HEK-CaSR membrane protein solution was added and preincubated at 4°C for 2 h. Binding assay buffer or cold upacicalcet containing binding assay buffer (final concentration, 100 μM) was added to the beads/membrane protein solution. In addition, cold upacicalcet containing binding assay buffer (final concentration, 1.0 × 10–11–10–5 M), L-tryptophan containing binding assay buffer (final concentration, 0.03–30 mM) or cinacalcet HCl containing binding assay buffer (final concentration, 1.0 × 10–11–10–4 M) was added, and 15,000 dpm of [3H]-upacicalcet was added and allowed to react for 60 min at room temperature. MicroBeta2 (Perkin Elmer) was used to count the measured values, and the specific binding was calculated from the obtained values using the following formula. The IC50 values of upacicalcet and L-tryptophan were calculated using GraphPad Prism (GraphPad Software, version 6.05) based on the obtained values. Each test was performed three times with triplicate measurements per concentration point.

Specific binding (cpm) = Total bindings3 − Nonspecific bindings4

3: Counts in the absence of cold upacicalcet (cpm)
4: Counts in the presence of cold upacicalcet (cpm)

Evaluation of upacicalcet relative binding abilities to WT and various mutant CaSR proteins using a scintillation proximity assay. WGA PEI Type A PVT SPA Scintillation Beads were suspended in binding assay buffer, and various Trans-HEK membrane protein suspensions were added and preincubated at 4°C for 2 h. Binding assay buffer or cold upacicalcet containing binding assay buffer (final concentration, 100 μM) was added to the beads/membrane protein solution. Next, 40,000 dpm of [3H]-upacicalcet was added and allowed to react for 60 min at room temperature. MicroBeta2 (Perkin Elmer) was used to count the measured values, and the specific binding was calculated from the obtained values using the same formula as previously described. The relative binding ability of each mutant CaSR protein was calculated using the following formula when the specific binding of upacicalcet to WT CaSR obtained in the all test was set at 100%. Each test was performed three times with triplicate measurements per concentration point.

Relative binding (%) = \frac{\text{Specific Binding of mutant CaSR (cpm)}}{\text{Specific Binding of WT CaSR (cpm)}} \times 100

Statistical differences in the relative binding of upacicalcet to each mutant CaSR versus WT CaSR were determined by a one-way analysis of variance followed by the Dunnett’s multiple comparison, and P values < 0.05 were to be considered statistically significant.

Molecular Docking Study. Molecular docking was performed using the Schrödinger package program (Schrödinger LLC, New York). A three-dimensional model of upacicalcet was generated using the LigPrep program in the Schrödinger suite. The ligands were minimized by the OPLS3e force field (Roos et al., 2019). The CaSR ECD crystal structures (PDB 5KSS, 5FBH, and 5FBK; all three crystal structures were reported previously by the other research groups; Geng et al., 2016; Zhang et al., 2016) were prepared using the Protein Preparation Wizard program in the Schrödinger suite (Sastry et al., 2013). All water molecules were deleted. In addition, Ca2+ at calcium binding site 2 was modified to Cl− in PDB 5KSS and Ca2+ at the calcium binding site 3 in both PDB 5KSS and 5FBK were deleted (Geng et al., 2016; Zhang et al., 2016). Induced fit docking was performed using the automated extended sampling protocol in the Schrödinger suite (Sherman et al., 2006). This first performs several initial dockings with the side chains either removed and with the van der Waals potential softened according to their flexibility. The side chains are then rebuilt, and those within 5 Å of the ligand are optimized using Prime program in the Schrödinger suite. The ligand was redocked into the new receptor structure using the Glide SP algorithm in the Schrödinger suite (Friesner et al., 2004) and a standard potential. The receptor grid was centered on the L-tryptophan (PDB 5KSS) or the cyclohexyltrypthophan (PDB 5FBH, 5FBK) and was generated using the OPLS3e force field (Roos et al., 2019). Upacicalcet was docked to chain A and B of PDB 5KSS, 5FBH, and 5FBK using the extended sampling protocol and the following core constraints: the alpha-amino group, carbonyl group, alpha-carbon, and beta-carbon of the ligand in the coenzyme structure had to overlap with the root mean square deviation (RMSD) within 1 Å.

Ligand–Protein Interaction Analysis of Docking Poses. To derive the interaction fingerprints of all docking poses, we used Maestro’s “Interaction Fingerprint Panel” in the Schrödinger suite (Deng et al., 2004; Singh et al., 2006). This method uses bits to describe the presence of different kinds of chemical interactions between the ligand and the binding site residues of the target receptor. For this purpose, a distance cutoff value is defined for the binding site, and residues containing atoms within the specified cutoff distance from the ligand atom are included in the interaction set. In this study, we used only the interaction fingerprints of the sidechain interaction because we were interested in changes in relative binding abilities resulting from amino acid substitutions in CaSR. To select amino acids in CaSR with the potential to interact with upacicalcet, the interaction fingerprints of the sidechain interaction were used for the output docking poses to determine the frequency of the interacting amino acids. We also used the interaction fingerprints of the sidechain interaction to filter out docking poses that were consistent with the relative binding abilities to mutant CaSR proteins.

IP-1 Measurement. The intracellular accumulation of IP-1 was measured using the Homogeneous Time Resolution Fluorescence IP-one Tb kit (Cisbio). This assay quantifies the accumulation of IP-1, a degradation product of inositol 1,4,5-trisphosphate (IP-3), and is stable in the presence of LiCl (Zhang et al., 2010). HEK cells were transiently transfected with plasmids encoding WT or mutant full-length CaSR using the same procedure as that used to prepare the membrane proteins. After overnight incubation at 37°C and 5% CO2, the medium was removed and each concentration of Ca2+ and presence or absence of 100 μM upacicalcet solutions dissolved in assay buffer (1 × Hank’s balanced salt solution, 20 mM HEPES, 1 mM MgSO4, 50 mM LiCl, 0.1% bovine serum albumin) were added and incubated at 37°C and 5% CO2 for 2 h. After that, IP1-d2 conjugate and anti-IP1 cryptate were added and mixed well, and the fluorescence intensity (fluorescence wavelength: 665/620 nm) was measured using a luminescence fluorescence plate reader (POWERSCAN4, DS pharma). From the obtained fluorescence intensity, the ratio at each concentration point was calculated according to the following formula.

\[
\text{Ratio} = \frac{\text{Fluorescence 665 nm}}{\text{Fluorescence 620 nm}} \times 10,000
\]

The IP-1 concentration (nmol/L) at each concentration point was calculated using the 4-parameter calibration curve by GraphPad Prism (GraphPad Software, version 6.05) based on the ratios of the standard CaSR measured simultaneously. The IP-1 ratio (%) of each mutant CaSR was calculated based on the WT IP-1 concentration of Emax as 100%. Each test was performed in duplicate at each concentration point, and the measurements were repeated three times except in the case where the concentration-dependent IP-1 accumulation disappeared by the mutation.
**Molecular Dynamics Simulations.** Molecular dynamics simulations of the selected docking poses were performed using the Desmond program in the Schrödinger suite (Bowers et al., 2006). Each protein-ligand complex was placed in a cubic box with a buffer distance of 10 Å to create a hydration model and ionized to a concentration of 0.15 M NaCl. The overall charge of each system was neutralized by the addition of Na\(^+\) or Cl\(^-\) ions, as appropriate.

The OPLS3e all-atom force field (Roos et al., 2019) was used to describe all molecules. For water, the simple point charge model (Jorgensen et al., 1983) was used to model hydration. For system minimization and relaxation, the NPT ensemble was used. Each simulation was run for a total of 120 ns, and the simulations were repeated three times for each system. Temperature and pressure were kept constant at 300 K and 1.01325 bar, respectively, throughout the simulation. The data analyses, such as RMSD and the ligand interaction fingerprints, were performed using the simulation interaction diagram program in the Schrödinger suite.

**Results**

**Upacicalcet Is a Positive Allosteric Modulator for CaSR.** Upacicalcet is an amino acid-derived compound that was discovered during the study of the “kokumi-flavor” of γ-glutamyl peptides, such as glutathione (Ueda et al., 1997). While glutathione analogs have a linear skeleton, upacicalcet has an aromatic ring, and its structure is similar to that of aromatic amino acids such as L-tryptophan (Fig. 1A). In addition, amino acids and glutathione analogs are known to have positive allosteric effects on CaSR, and similar positive allosteric effects have been also reported for cinacalcet (Conigrave et al., 2002, 2004, 2006; Nemeth et al., 2004; Broadhead et al., 2011; Amino et al., 2016). First, to characterize the agonistic activity of upacicalcet for CaSR, we evaluated the effect of human CaSR on extracellular Ca\(^{2+}\) concentration-dependent intracellular Ca\(^{2+}\) mobilization in the presence of upacicalcet in HEK-293 cells. At an extracellular Ca\(^{2+}\) concentration of 0.1 mM, upacicalcet did not affect intracellular Ca\(^{2+}\) mobilization up to 1000 nM; at concentrations of 0.4 mM of extracellular Ca\(^{2+}\) or higher, however, upacicalcet increased intracellular Ca\(^{2+}\) mobilization in a concentration-dependent manner (Fig. 2). On the other hand, the maximum effect of intracellular Ca\(^{2+}\) mobilization was unchanged with or without upacicalcet treatment. These data indicate that while upacicalcet does not activate CaSR in the low extracellular Ca\(^{2+}\) concentration range (<0.1 mM), it does enhance Ca\(^{2+}\) action in the high Ca\(^{2+}\) concentration range. Thus, upacicalcet is a pure positive allosteric modulator that enhances CaSR signaling in an extracellular Ca\(^{2+}\) concentration-dependent manner, without exerting agonist effects on CaSR.

**Upacicalcet and Tryptophan Bind to the Same Binding Site of CaSR.** Since upacicalcet is a positive allosteric modulator of CaSR similar to amino acids and the chemical structure of upacicalcet is similar to that of aromatic amino acids, we hypothesized that the binding site of upacicalcet is the same as that for amino acids. To confirm this hypothesis, the effect of L-tryptophan on the binding ability of upacicalcet to CaSR was evaluated using a scintillation proximity assay. First, to confirm the binding of upacicalcet to CaSR, we performed a competition study between cold and \(^{[3]}\)H-upacicalcet using HEK-CaSR and HEK membrane proteins. The results showed specific binding only to the HEK-CaSR membrane protein, and the binding was inhibited in a concentration-dependent manner by cold upacicalcet (IC\(_{50}\): 8.2 nM) (Fig. 3A; Supplemental Table 1). Additionally, the specific binding of upacicalcet with human CaSR was reduced with the addition of L-tryptophan in a concentration-dependent manner (IC\(_{50}\): 4.3 mM) (Fig. 3B, Supplemental Table 1). On the other hand, cinacalcet did not affect the binding of upacicalcet to human CaSR at concentrations of up to 100 μM (Fig. 3C).

**Prediction of Residues Thought to Be Important for Upacicalcet Binding Based on the Crystal Structure of the CaSR ECD Region.** The specific binding of upacicalcet to CaSR was inhibited by L-tryptophan in a
concentration-dependent manner, strongly suggesting that upacicalcet acts on the amino acid binding site in the extracellular region of CaSR. Therefore, we elucidated the detailed binding mode of upacicalcet to CaSR. We evaluated the effect of alanine substitutions at amino acid residues of CaSR that were thought to be important for upacicalcet binding on the actual relative binding abilities of [3H]-upacicalcet to mutant CaSR-HEK membrane fractions.

To select the mutation site of CaSR, docking studies comparing upacicalcet and the previously reported crystal structure of the ECD region of CaSR (Geng et al., 2016; Zhang et al., 2016) were performed. As a result, a total of 276 docking poses were output. The breakdown was 49 and 47 poses for PDB 5K5S chain A and chain B; 40 and 49 poses for PDB 5FBH chain A and chain B; and 42 and 49 poses for PDB 5FBK chain A and chain B, respectively (Fig. 4). Then, to determine the amino acid side chains that may interact with upacicalcet, the frequency of interaction of each amino acid was confirmed by calculating the interaction fingerprints of the sidechain interaction for all docking poses (Table 1). The amino acids that frequently interacted with upacicalcet or that are known to interact with L-tryptophan and cyclometthyltryptophan were selected as candidate substitution sites (Geng et al., 2016; Zhang et al., 2016) except for Tyr218 and Asn64, which were considered to have low priorities based on the binding mode of L-tryptophan, the structure of the residues, and the distance between the molecules. As a result of this analysis, eight amino acids (Arg66, Trp70, Ser147, Ser170, Ser272, Glu297, Ser302, and Ile416) were selected as alanine mutation sites in CaSR (Figs. 4 and 5). Additionally, Cys482, the binding site of etelcalcetide (Alexander et al., 2015), and Glu837, that of cinacalcet (Leach et al., 2016), were selected as mutation targets for the evaluation of mutated CaSR proteins.

Several of the Amino Acid Residues That Form the Amino Acid Binding Site of CaSR Are Important for the Binding of Upacicalcet. Plasmid vectors encoding various full-length CaSR proteins were introduced into HEK-293 cells to express the various mutated CaSR proteins. The expressions of the various CaSR proteins were evaluated using western blotting. First, the specificity of the antibody was confirmed by evaluating the whole proteins of HEK-CaSR, HEK, and HEK-WT expressing WT CaSR (Supplemental Fig. 1). Then, the amounts of expressed various mutant CaSR proteins were evaluated, and there was no difference in expression levels (Fig. 6A). Subsequently, we examined the effect of substitutions (C482Y, etelcalcetide binding residue; E837A, cinacalcet binding residue) in CaSR on the binding ability of upacicalcet. The relative binding of [3H]-upacicalcet to the mutated CaSR proteins did not decrease for either substitution when the WT binding ability was 100% (Fig. 6B).
We then evaluated the effects of alanine substitutions at residues Ser147 and Ser170 in the extracellular region of CaSR, as these residues are known to be important for the binding of amino acids to CaSR (Zhang et al., 2002; Silve et al., 2005; Geng et al., 2016). As a result, the relative binding abilities to W70A and E297A were significantly decreased to \( \approx 20\% \) of that seen for WT CaSR; these results were comparable to those for S147A and S170A. The relative binding to I416A also showed a significant decrease to about 30\% of that for the WT CaSR (Fig. 6B).

Finally, we evaluated the effects of alanine substitutions at three amino acid residues, Arg66, Ser272, and Ser302; these residues were selected as a result of previously reported induced fit docking between the crystal structure of the ECD region of CaSR (Geng et al., 2016; Zhang et al., 2016) and upacicalcet, as shown in Table 1. R66A showed a significant decrease (\( P < 0.001 \)) in upacicalcet binding ability to about 30\% of that for WT CaSR. S302A also showed a significant (\( P < 0.05 \)) decrease in binding ability; however, the effect was quite weak compared with that of other residues (approximately \( \approx 40\% \) reduction vs. WT CaSR). Furthermore, no decrease in upacicalcet binding ability was observed for S272A (Fig. 6B). When the structure of upacicalcet was compared with those of aromatic amino acids, such as L-tryptophan and phenylalanine, these residues were thought to interact with methyl, chloro, and sulfo groups, which are characteristic of upacicalcet only, and Arg66 was especially important.

**IP-1 Assay Results for Each Mutant CaSR Protein**

**Support the Binding Ability Results.** The previous results suggested that upacicalcet binds to the amino acid binding site of CaSR and that the CaSR residues that are important for this binding are as follows: (1) residues that interact with amino acid alpha-amino and carboxyl groups (Ser147, Ser170), (2) residues that commonly interact with aromatic amino acids such as L-tryptophan (Trp70, Glu297, Ile416), and (3) residues that interact only with upacicalcet (Arg66). We attempted to improve the confidence of the relative binding ability results by evaluating the functional binding ability of mutant CaSR proteins.

**TABLE 1.**

Result of ligand-protein interaction analysis of docking poses

<table>
<thead>
<tr>
<th>Amino Acid Residue of CaSR</th>
<th>Frequency of Interaction</th>
<th>Interaction with L-tryptophan</th>
</tr>
</thead>
<tbody>
<tr>
<td>Asn64</td>
<td>66</td>
<td>Presence</td>
</tr>
<tr>
<td>Arg66</td>
<td>88</td>
<td>Presence</td>
</tr>
<tr>
<td>Trp70</td>
<td>74</td>
<td>Presence</td>
</tr>
<tr>
<td>Asn102</td>
<td>14</td>
<td>Presence</td>
</tr>
<tr>
<td>Thr145</td>
<td>37</td>
<td>Presence</td>
</tr>
<tr>
<td>Ser147</td>
<td>89</td>
<td>Presence</td>
</tr>
<tr>
<td>Ala168</td>
<td>22</td>
<td>Presence</td>
</tr>
<tr>
<td>Ser170</td>
<td>89</td>
<td>Presence</td>
</tr>
<tr>
<td>Ile187</td>
<td>2</td>
<td>Presence</td>
</tr>
<tr>
<td>Tyr218</td>
<td>89</td>
<td>Presence</td>
</tr>
<tr>
<td>Ser272</td>
<td>63</td>
<td>Presence</td>
</tr>
<tr>
<td>Asp275</td>
<td>1</td>
<td>Presence</td>
</tr>
<tr>
<td>Glu297</td>
<td>32</td>
<td>Presence</td>
</tr>
<tr>
<td>Ala298</td>
<td>84</td>
<td>Presence</td>
</tr>
<tr>
<td>Ser301</td>
<td>48</td>
<td>Presence</td>
</tr>
<tr>
<td>Ser302</td>
<td>83</td>
<td>Presence</td>
</tr>
<tr>
<td>Ser303</td>
<td>16</td>
<td>Presence</td>
</tr>
<tr>
<td>Ala321</td>
<td>4</td>
<td>Presence</td>
</tr>
<tr>
<td>Arg415</td>
<td>12</td>
<td>Presence</td>
</tr>
<tr>
<td>Ile416</td>
<td>50</td>
<td>Presence</td>
</tr>
</tbody>
</table>
aspects of the receptor as well. We transfected HEK-293 cells with plasmid vectors encoding WT or mutant forms of CaSR, as in the relative binding ability evaluation, and generated HEK-293 cells transiently expressing these mutated CaSR proteins. The effect of each mutation on calcium signaling and the effect of upacicalcet (100 μM) on calcium signaling were evaluated using the intracellular accumulation of IP-1 as an indicator. Intracellular calcium release is frequently triggered by non-G-protein mechanisms such as Ca2+-permeable channels, calcium pumps, and calcium transporters, so optimization of the evaluation system is necessary to measure Ca2+ responsiveness. The IP-1 assay measures IP-1 rather than the short-lived IP-3 generated by the phospholipase C pathway via GPCR Gq signaling, in which the IP-3–IP-2–IP-1–inositol dephosphorylation pathway is stopped by the addition of lithium chloride and accumulates in IP-1. An IP-1 assay is often used to measure the activity of GPCRs including CaSR (Zhang et al., 2010; Walter et al., 2013; Geng et al., 2016). In addition, the concentration of upacicalcet added (100 μM) was selected under conditions at which the WT was fully saturated in the pre-test of the IP-1 assay for the purpose of confirming the maximum effect of the WT and the mutant.

First, we confirmed the effect of Ca2+ and upacicalcet in HEK-293T cells transiently expressing WT CaSR. As a result, we observed an extracellular Ca2+ concentration-dependent accumulation of IP-1 and a shift in the sigmoid function toward a lower concentration in the presence of upacicalcet (Fig. 7A). In this manner, we confirmed the validity of the assay method and the positive allosteric effect of upacicalcet. We then evaluated the effects of substitutions (C482Y, E837A) at the CaSR site where upacicalcet binds. Similar to previous reports (Alexander et al., 2015; Jacobsen et al., 2017), no change for C482Y and E837A were observed (Supplemental Fig. 2A). In the presence of upacicalcet, the Emax was slightly decreased for E837A, compared with the WT, but no change was observed for C482Y (Fig. 7B). Next, we evaluated S147A, S170A, and E297A, which have been reported as protein mutations that significantly reduce the Ca2+ response (Silve et al., 2005; Geng et al., 2016; Zhang et al., 2002) (Supplemental Fig. 2B). Surprisingly, S147A, S170A, and E297A conferred a marked recovery effect on Ca2+ responsiveness in the presence of upacicalcet (Fig. 7C). Reportedly, the change in Ca2+ response conferred by W70A is also greatly decreased, similar to the previous results observed for S147A, S170A, and E297A (Ling et al., 2021). We also observed a significant decrease in the Ca2+ response in the presence of W70A (Supplemental Fig. 2C). However, the recovery of Ca2+ responsiveness in the presence of W70A and upacicalcet was less marked, unlike the
results seen for S147A, S170A, and E297A (Fig. 7D). Although previous findings regarding Ca\(^{2+}\) responsiveness in the presence of I416A and upacicalcet are not available, no changes were observed in our study (Supplemental Fig. 2C). On the other hand, Ca\(^{2+}\) responsiveness in the presence of upacicalcet was decreased (Fig. 7D). Furthermore, Ca\(^{2+}\) responses to the R66A, S272A, and S302A substitutions were unchanged or showed a slight decrease (Supplemental Fig. 2D). The substitution of Arg66 with histidine has been reported to decrease the Ca\(^{2+}\) response (Geng et al., 2016). Ca\(^{2+}\) responsiveness in the presence of upacicalcet was decreased for R66A, slightly decreased for S302A, and unchanged for S272A, compared with the WT (Fig. 7E).

The results of the IP-1 assay in the presence of upacicalcet paralleled the relative binding results closely. In particular, mutations resulting in a large decrease in relative binding ability also caused a large decrease in Ca\(^{2+}\) responsiveness in the presence of upacicalcet in the IP-1 assay. However, mutations targeting three residues (Ser147, Ser170, and Glu297), which are considered important for amino acid binding, resulted in a strong Ca\(^{2+}\) response recovery. Although aromatic amino acids have been shown to have a weak effect on Ca\(^{2+}\) response recovery in previous reports (Zhang et al., 2002; Silve et al., 2005), the effect of upacicalcet was much more potent than that of aromatic amino acids. As an additional test, we evaluated the effect of amino acids on the recovery of Ca\(^{2+}\) responsiveness to mutant CaSR protein (S170A), the Ca\(^{2+}\) response for which was greatly reduced in the IP-1 assay. As a result, in the presence of 50 mM of L-tryptophan, there was a slight recovery of the Ca\(^{2+}\) response in the high concentration range of extracellular Ca\(^{2+}\). On the other hand, no recovery was observed in the presence of 50 mM of glycine (data not shown).

Binding Mode of Upacicalcet to CaSR. Based on the results of the previous studies and using molecular dynamics simulations, we found a binding mode that is consistent with the experimental results. In brief, we considered interacting residues (Arg66, Trp70, Ser147, Ser170, Glu297, and Ile416) that clearly showed reduced binding ability and activity in the IP-1 assay compared with WT. In addition, we considered that Ser302, which showed a slight decrease in binding ability, and Ser272, which showed no decrease, did not contribute as much to the binding of upacicalcet to CaSR compared with other residues, and we searched for binding modes that did not interact with these residues. From the 273 poses output in the docking study, we used Sidechain interaction in interaction fingerprints to narrow down the docking poses that interacted with the side chains of Arg66, Trp70, Ser147, Ser170, Glu297, and Ile416, which had a significant difference (P < 0.001) in the relative binding results and did not interact with the side chains of Ser272 and Ser302 (Fig. 4). As a result, three poses were selected. These were all from the PDB 5FBH chain B docking study and were the 31st, 37th, and 49th docking poses from the top, respectively (Fig. 4). For these poses, we performed molecular dynamics simulations three times at 120 ns to check whether the hydrogen bonds were maintained between the carbonyl group of upacicalcet and the main chain amine of Ser147, the side chain hydroxyl group of Ser147, and the main chain amine of Ser170, as well as between the alpha-amino group of upacicalcet and the side chain hydroxyl group of Ser170 and the main chain carbonyl of Ala168. When poses that maintained >30% of the interaction were considered as the appropriate binding mode, only the rank 37 docking pose maintained the interaction in three molecular dynamics simulations (Figs. 4 and 8; Supplemental Fig. 3).

Our proposed binding mode of CaSR to upacicalcet is shown in Fig. 9. The amino acid backbone of upacicalcet are similar to those of L-tryptophan and cyclomethyltryptophan. The carbonyl group of upacicalcet forms hydrogen bonds with the main chain amine of Ser147, the side chain hydroxyl group, and the main chain amine of Ser170, respectively, and the alpha-amino group of upacicalcet forms hydrogen bonds with the side chain hydroxyl group of Ser170 and the main chain carbonyl of Ala168, respectively. The side chain carbonyl group of Glu297, which formed hydrogen bonds with the amine of the indole ring in L-tryptophan, formed hydrogen bonds with each of the two amine groups of urea in the case of upacicalcet, and it also formed hydrogen bonds or ionic bonds with the alpha-amino group of upacicalcet. There are two specific interactions for upacicalcet: one is the sulfo group of upacicalcet, which forms hydrogen bonds with the side chain guanidyl group of Arg66, the main chain amine of Leu322, and also forms water-mediated hydrogen bonds with the main chain carbonyl of Phe320, and the other is the carbonyl group of the urea of upacicalcet, which forms water-mediated hydrogen bonds with the hydroxyl group of the side chain of Thr145. In addition, the benzene ring of upacicalcet was
closer to Ile416 than the benzene rings of L-tryptophan and cyclomethyltryptophan. We suspect that there is a hydrophobic interaction between the indole ring of the Trp70 side chain and the benzene ring of the upacicalcet stacked in a T-shape (π-H stacking) and a hydrophobic interaction between the Ile416 side chain and the upacicalcet. The mutation causing I416A did not change the Ca$^{2+}$ responsiveness in the IP-1 assay but decreased the effect of

![Fig. 7. Effect of the mutation of CaSR protein on IP-1 accumulation of transiently CaSR expressing HEK-293T cells in the presence of upacicalcet. (A) Positive allosteric activity of upacicalcet on WT CaSR. Ca$^{2+}$ concentration-dependent IP-1 accumulation is shown (open circle, Ca$^{2+}$ only; closed circle, in the presence of 100 μM upacicalcet). (B–E) Comparison of IP-1 accumulation between WT and mutant CaSR in the presence of 100 μM upacicalcet. The percentage for each mutant CaSR protein based on an Emax of 100% for IP-1 accumulation in the WT is shown. (B) Closed circle, WT; closed triangle, C482Y; closed square, E837A. (C) Closed circle, WT; closed triangle, S147A; closed square, S170A; closed rhombus, E297A. (D) Closed circle, WT; closed triangle, W70A; closed square, I416A. (E) Closed circle, WT; closed triangle, R66A; closed square, S302A closed rhombus, S272A. The data are presented as the mean ± S.D. of three independent experiments measured in duplicate.](image-url)
Fig. 8. Estimation of upacicalcet binding mode based on molecular dynamics simulation (simulation 1). Two-dimensional summary of interaction analysis results of IFD rank 37 of PDB 5FBH chain B during 120 ns of molecular dynamics simulations. The interaction pairs that occur during more than 30% of the simulation time are included (top). The RMSD of protein and ligand relative to the starting complexes during 120 ns of molecular dynamics trajectory (bottom).
The functional groups of upacicalcet seem to penetrate further into the pocket, especially the sulfonate group and its interaction with Arg66 of CaSR. The main ligands for class C GPCRs such as CaSR are \( \alpha \)-amino acids. \( \alpha \)-amino acids fit into the amino acid binding pockets of many GPCRs and can cause dynamic conformational change. On the other hand, the amino acid binding sites of CaSR are larger than those of many GPCRs (Conigrave and Hampson, 2006), so \( \alpha \)-amino acids alone are not sufficient to induce conformational change. We believe that ligands that have a strong effect on CaSR need to interact with multiple residues that consist of the amino acid binding site. In fact, glutathione analogs, which are tripeptides, show stronger the maximum left shift of the Ca\(^{2+}\) concentration curve than amino acids (Broadhead et al., 2011; Amino et al., 2016). In this study reveals that upacicalcet interacts with more residues compared with \( \alpha \)-amino acids. When the structure–activity relationship of upacicalcet was examined, the maximum left shift of the Ca\(^{2+}\) concentration curve was greatly reduced when the sulfonate group was eliminated, suggesting that the interaction between the CaSR residue with the sulfonate group extending from the aromatic ring of upacicalcet is important for the much stronger CaSR positive allosteric activity, compared with that seen for aromatic amino acids.

**Discussion**

To define the binding mode of upacicalcet to CaSR, we hypothesized that upacicalcet works on the amino acid binding site of CaSR after focusing on two features: the chemical structure of upacicalcet is similar to that of amino acids, and upacicalcet is a positive allosteric modulator of CaSR. This study strongly suggests that upacicalcet acts on the amino acid binding site (Arg66, Trp70, Tyr145, Ala168, Ser170, Glu297, Phe320, Leu322, and Ile416) of CaSR. Trp70, Glu297, and Ile416, which reportedly interact with L-tryptophan (Geng et al., 2016), all showed significant reductions in relative binding abilities as a result of alanine substitution. Among amino acids, L-tryptophan is known to have strong positive allosteric activity in the presence of Ca\(^{2+}\) against CaSR (Conigrave et al., 2006). The hydrophobic interaction between the aromatic ring of the ligand and the hydrophobic residues of CaSR was considered to be important for binding, and a similar situation was suggested for upacicalcet. Furthermore, the interaction of the urea of upacicalcet with Glu297 of CaSR instead of the nitrogen atom of the indole ring of L-tryptophan is also likely to be important for binding. We evaluated the relative binding abilities of alanine substitutions at 3 amino acid residues, Arg66, Ser272, and Ser302, which were predicted to be of importance based on the results of a docking study between the ECD region of CaSR and upacicalcet. R66A resulted in a strong decrease in binding ability, although no decrease in binding ability was observed for S272A. Comparing the chemical structures of tryptophan and upacicalcet by overlapping the amino and carboxyl groups bound to the alpha carbon, upacicalcet is longer. The binding mode of upacicalcet is that the sulfonate group extending from the benzene ring is located near the amino acid binding site of Arg66 (Fig. 9A). Tryptophan cannot interact with Arg66 because of its small molecular size, and the interaction between the ligand and Arg66 is considered to be specific to upacicalcet (Fig. 5C, Fig. 9A).
In this study, we considered that Ser302 does not contribute to the binding of upacicalcet. It is possible that the test conditions affected the affinity of S302A-CaSR and upacicalcet, given that Ser302 has been reported as a calcium binding site (Geng et al., 2016). To find the exact binding mode of upacicalcet, it may be necessary to vary the concentration of calcium, phosphorus, etc., which have been reported as CaSR ligands. Among the calcimimetics, the IC$_{50}$ of L-tryptophan (approximately 2mM) and evocalcet (9.47 $\times$ 10$^{-8}$ M) were shown in previous reports (Geng et al., 2016; Leach et al., 2016). Comparison of these results shows that upacicalcet has a higher binding potency than L-tryptophan. The difference in binding potency between L-tryptophan and upacicalcet might be attributed to more interacting residues in the amino acid binding site with upacicalcet.

Amino acids are considered to act as a coagonist for CaSR in cooperation with Ca$^{2+}$. Aromatic amino acids that can interact more with CaSR are considered to be the primary players in vivo. Upacicalcet is expected to function in a manner similar to that of amino acids. Surprisingly, upacicalcet showed a strong Ca$^{2+}$ response recovery in an IP-1 assay even in the presence of mutant CaSR proteins (S147A, S170A, and E297A), the Ca$^{2+}$ responses of which are greatly decreased. This result may be due to the interaction of the sulfo group, benzene ring, and urea skeleton of upacicalcet with the residues constituting the amino acid binding site (Arg66, Trp70, Ile416, and Glu297, respectively), thereby compensating for the decrease in relative binding caused by mutations targeting some of the important amino acid binding sites.

These results strongly suggest that upacicalcet is a novel SHPT drug that binds to the amino acid binding site, unlike conventional drugs such as cinacalcet and etelcalcetide. As SNPs of CaSR have been reported to affect the pathophysiology of hemodialysis patients and the therapeutic effect, upacicalcet might be expected to be a new option for patients who do not respond well to conventional drugs (Grzegorzweska et al., 2016; Ngamkam et al., 2021).

CaSR has multiple calcium binding sites, and the affinity of each binding site for Ca$^{2+}$ is thought to change depending on the activation state of the receptor (Geng et al., 2016). Furthermore, the affinity of amino acids for CaSR is thought to depend on the extracellular Ca$^{2+}$ concentration (Geng et al., 2016). Upacicalcet might have a relatively low risk of adverse effects such as hypocalcemia, since it does not act excessively on CaSR, and its affinity may change depending on the extracellular Ca$^{2+}$ concentration. In fact, an in vitro validation of upacicalcet has confirmed that it exerts a pure positive allosteric effect that does not affect the $E_{\text{max}}$ and increases Ca$^{2+}$ sensitivity only at low Ca$^{2+}$ concentrations.

One group has shown that L-tryptophan alone does not activate CaSR but that the binding of L-tryptophan induces the closure of the Venus flytrap domain of CaSR, bringing the receptor to an intermediate active state, based on a single-particle cryo structural approach (Ling et al., 2021). In clinical study, the risk of hypocalcemia is often reported with etelcalcetide, which binds to the extracellular region (Bushinsky et al., 2020), but the incidence of hypocalcemia was low in the clinical trials of upacicalcet (Hoy, 2021). The difference in the effects of etelcalcetide and upacicalcet on CaSR in vitro (agonist or purely positive allosteric effect) is consistent with the results of clinical studies. This information indicates that upacicalcet acts to “wake up” the CaSR in a diminished or inactivated state, and it could be a safe drug for “awakened” CaSR, since there is a low risk of causing a “runaway” state of activation.

Arg66 and Trp70 have been reported as amino-binding residues in upacicalcet, and anions such as PO$_4^{3-}$ and SO$_4^{2-}$ are considered to be among the molecules that affect the conformation of CaSR (Geng et al., 2016; Centeno et al., 2019). In particular, phosphate ions stabilize the inactivated state of CaSR, suggesting that CaSR function is impaired in patients with hyperphosphatemia (Centeno et al., 2019). Recently, CaSR has been reported to function as a cation sensor for calcium, magnesium, and cadmium as well as an anion sensor for phosphate ion and others (Centeno et al., 2019). One of the important pathologies of SHPT is ectopic calcification, which is caused by the formation of insoluble salts of calcium and phosphate ions in the blood. In patients with hyperphosphatemia, the CaSR function is impaired, and the calcium sensor does not work properly, which may lead to excessive PTH secretion (Go et al., 2004; Cunningham et al., 2011). In the inactivated state, the amino acid binding site of CaSR might be more approachable, facilitating the binding of upacicalcet. In addition, the interaction of upacicalcet with anion-binding residues such as Arg66 and Trp70 is expected to release the inactivated state of CaSR and to promote a transition to the activated state. Upacicalcet is also expected to suppress these negative spirals by approaching the CaSR, which is impaired due to high phosphorus and high calcium levels. In the future, clarification of the interaction between upacicalcet and CaSR ligands, such as anions, may help to consider the clinical details of the drug’s effect.

In conclusion, upacicalcet shows a strong positive allosteric effect by interacting with the amino acid binding site of CaSR. The binding mode of upacicalcet involves interactions with several residues that constitute the amino acid binding site of CaSR. In addition to residues participating in known interactions between aromatic amino acids and CaSR, the interaction residues possessed only by upacicalcet are thought to be responsible for its much higher positive allosteric activity, relative to that of amino acids. Since this mechanism differs from those of conventional drugs, upacicalcet can be considered as a novel SHPT drug that acts on the amino acid binding site of CaSR.

Acknowledgments

The authors thank Nahika Tanaka and Minami Inagaki for the kind support to conduct the in vitro experiments in this study.

Authorship Contributions

Participated in research design: Sato, Murakami, Nishimura, Goto, Takahashi.
Conducted experiments: Sato, Murakami, Horii. Iwai.
Performed data analysis: Sato, Murakami, Horii.
Wrote or contributed to the writing of the manuscript: Sato, Murakami, Goto.
References


Address correspondence to: Moritaka Goto, Pharmaceuticals Research Laboratories, Sanwa Kagaku Kenkyusho Co., Ltd., 363 Shiosaki, Hokusetsu, Inabe, Mie, 511-6406, Japan. E-mail: mc.goto6@skk-net.com